{"id":477445,"date":"2020-04-02T12:18:01","date_gmt":"2020-04-02T12:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477445"},"modified":"2020-04-02T12:18:01","modified_gmt":"2020-04-02T12:18:01","slug":"refractory-angina-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/refractory-angina-epidemiology-forecast-to-2030_477445.html","title":{"rendered":"Refractory Angina Epidemiology Forecast to 2030"},"content":{"rendered":"
\"Refractory<\/a><\/div>\n

DelveInsight has launched a new report on  Refractory Angina<\/span> Epidemiology Forecast to 2030<\/span><\/strong><\/strong><\/p>\n

DelveInsight’s ‘ Refractory Angina – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Refractory Angina epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

The Refractory Angina market report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Refractory Angina treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Refractory Angina (RA)<\/strong> is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart.Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease(CAD). <\/p>\n

Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causespoor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization. Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong><\/em>free sample page<\/a><\/p>\n

Understanding <\/strong><\/p>\n

The DelveInsight Refractory Angina epidemiology report gives a thorough understanding of the Refractory Angina by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Refractory Angina in the US, Europe, and Japan. The report covers the detailed information of the Refractory Angina epidemiology scenario in seven major countries (US, EU5, and Japan).<\/p>\n

Epidemiology Perspective <\/strong><\/p>\n

The Refractory Angina epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Refractory Angina epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Refractory Angina epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.<\/p>\n

Epidemiology Segmentation<\/strong><\/p>\n

The Refractory Angina epidemiology covered in the report provides historical as well as forecasted Refractory Angina epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.<\/p>\n

The DelveInsight Refractory Angina report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.<\/p>\n

Key companies working on Refractory Angina that are given below:-<\/em><\/strong><\/p>\n

1. <\/em><\/strong>Imbria Pharmaceuticals<\/em><\/p>\n

2. Caladrius Biosciences, Inc<\/em><\/p>\n

3. XyloCor Therapeutics, Inc<\/em><\/p>\n

Name of drugs covered that are given below:-<\/em><\/strong><\/p>\n

1. IMB-101<\/em><\/p>\n

2. Auto CD34+ Cells<\/em><\/p>\n

3. XC001<\/em><\/p>\n

Table of contents<\/a><\/p>\n

1. Key Insights<\/span> <\/p>\n

2. Executive Summary of Refractory Angina<\/span><\/p>\n

3.  Refractory Angina: Disease Background and Overview<\/span><\/p>\n

3.1. Introduction<\/span><\/p>\n

3.2. Sign and Symptoms<\/span><\/p>\n

3.3. Pathophysiology<\/span><\/p>\n

3.4. Risk Factors<\/span><\/p>\n

3.5. Diagnosis<\/span><\/p>\n

4. Patient Journey<\/span><\/p>\n

5. Epidemiology and Patient Population<\/span><\/p>\n

5.1. Epidemiology Key Findings<\/span><\/p>\n

5.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

5.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

5.3.1.  Refractory Angina Epidemiology Scenario in the 7MM (2017- 2030)<\/span><\/p>\n

5.4. United States Epidemiology<\/span><\/p>\n

5.4.1.  Refractory Angina Epidemiology Scenario in the United States (2017- 2030)<\/span><\/p>\n

5.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

5.5.1. Germany Epidemiology<\/span><\/p>\n

5.5.1.1.  Refractory Angina Epidemiology Scenario in Germany (2017- 2030)<\/span><\/p>\n

5.5.2. France Epidemiology<\/span><\/p>\n

5.5.2.1.  Refractory Angina Epidemiology Scenario in France (2017- 2030)<\/span><\/p>\n

5.5.3. Italy Epidemiology<\/span><\/p>\n

5.5.3.1.  Refractory Angina Epidemiology Scenario in Italy (2017- 2030)<\/span><\/p>\n

5.5.4. Spain Epidemiology<\/span><\/p>\n

5.5.4.1.  Refractory Angina Epidemiology Scenario in Spain (2017- 2030)<\/span><\/p>\n

5.5.5. United Kingdom Epidemiology<\/span><\/p>\n

5.5.5.1.  Refractory Angina Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

5.6. Japan Epidemiology<\/span><\/p>\n

5.6.1.  Refractory Angina Epidemiology Scenario in Japan (2017- 2030)<\/span><\/p>\n

6. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

6.1.  Refractory Angina Treatment and Management<\/span><\/p>\n

6.2.  Refractory Angina Treatment Algorithm<\/span><\/p>\n

7. KOL Views<\/span><\/p>\n

8. Unmet Needs<\/span><\/p>\n

9.  Appendix<\/span><\/p>\n

9.1. Bibliography<\/span><\/p>\n

9.2. Report Methodology<\/span><\/p>\n

10. DelveInsight Capabilities<\/span><\/p>\n

11. Disclaimer<\/span><\/p>\n

12. About <\/strong>DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/em><\/p>\n